Is InflaRx N.V. (IFRX) a Buy, Sell, or Hold?
NASDAQ : IFRX
InflaRx N.V.
$1.91 USD
-$0.11 (-5.45%)
- Volume
- 715.63K
- Average Volume
- 2.08M
- Market Capitalization
- $137.97M
- P/E Ratio
- -2.74
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $2.95
- Year Low
- $0.74
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.16
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Niels C. Riedemann |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IFRX |
| CUSIP | N44821101 |
| CIK | 0001708688 |
| Web | https://www.inflarx.de |
| Phone | 49 3641 508 180 |
| Currency | USD |
| Employees | 65 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Cash Ratio | 1.32 |
Sales & Book Value
| Annual Sales | $29331 |
| Price / Sales | 4109.68 |
| Cash Flow | -0.40 |
| Price / Cash Flow | -4.17 |
| Price / Book | 3.27 |
Price Target and Rating
| Average Stock Price Forecast | $9.00 |
| High Stock Price Forecast | $9.00 |
| Low Stock Price Forecast | $9.00 |
| Forecast Upside/Downside | -78.78% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.66 |
| Trailing P/E Ratio | -2.74 |
| PEG Ratio | -0.15 |
| P/E Growth | -0.15 |
| Net Income | -$45.63M |
| Net Margin | -146303.92% |
| Pretax Margin | -145945.54% |
| Return on Equity | -94.90% |
| Return on Assets | -87.68% |
Financials Score
| AltmanZ Score | -6.96 |
| Piotroski Score | 1.00 |
| Working Capital | 36.04M |
| Total Assets | 48.94M |
| Ebit | -42.76M |
| Market Cap | 120.53M |
| Total Liabilities | 12.01M |
Poll Results
About InflaRx N.V. (NASDAQ:IFRX) Stock
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil ... cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
2026-06-30 07:30:00
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessment given the recommendation of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the European Union, announced on June 26, 2026.
2026-05-08 21:51:14
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
2026-05-08 16:04:36
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Get InflaRx alerts:Sign UpIzicopan positioned as a next-generation C5aR inhibitor Riedemann described izicopan as an oral agent designed to block the C5a receptor, a pathway he called a “critical driver of inflammatory cascade.
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
2026-05-08 08:15:00
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
2026-05-06 08:30:00
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share.
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
2026-05-06 08:25:00
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it intends to develop izicopan, an oral C5a receptor (C5aR) inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV and is evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan.
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
2026-05-04 07:30:00
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk.
InflaRx to Report First Quarter 2026 Results on May 7, 2026
2026-05-01 07:30:00
JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the first quarter 2026 on May 7, 2026, before the market opens. No conference call is planned.
Frequently Asked Questions
-
What is the current InflaRx N.V. (IFRX) stock price?
-
InflaRx N.V.(NASDAQ:IFRX) stock price is $1.91 in the last trading session. During the trading session, IFRX stock reached the peak price of $2.949 while $0.741 was the lowest point it dropped to. The percentage change in IFRX stock occurred in the recent session was --5.45% while the dollar amount for the price change in IFRX stock was -$0.11.
-
IFRX's industry and sector of operation?
-
The NASDAQ listed IFRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IFRX?
-
Derval O'Carroll | Senior Vice President and Global Head of Regulatory Affairs & Compliance
Niels C. Riedemann | Co-Founder, Chief Executive Officer & Executive Director
Daniel Vetter | Senior Director & Head of IT
Peter Hurt | Senior Director and Head of Drug Safety & Pharmacovigiliance
Renfeng Guo | Co-Founder, Chief Scientific Officer & Executive Director -
How many employees does IFRX have?
-
Number of IFRX employees currently stands at 65. IFRX operates from Winzerlaer Str. 2, Jena, TH 07745, DE.
-
Link for IFRX official website?
-
Official Website of IFRX is: https://www.inflarx.de
-
How do I contact IFRX?
-
IFRX could be contacted at phone #49 3641 508 180 and can also be accessed through its website. IFRX operates from Winzerlaer Str. 2, Jena, TH 07745, DE.
-
How many shares of IFRX are traded daily?
-
The average number of IFRX shares traded daily for last 3 months was 2.08M.
-
What is the market cap of IFRX currently?
-
The market value of IFRX currently stands at $137.97M with its latest stock price at $1.91